*YUJI YAMADA1, Kazuo Mishima2, Takashi Ohnishi3, Takahiro Nemoto4, Masafumi Mizuno5, Toshifumi Kishimoto6, Hiroaki Tomita7, Motohiro Ozone8, Shingo Kitamura10, Kenji Hashimoto9, Kazuyuki Nakagome1, Tomiki Sumiyoshi10
(1. Department of Psychiatry, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan, 2. Department of Neuropsychiatry, Akita University Graduate School of Medicine, Akita, Japan, 3. Medical Affairs Division, Janssen Pharmaceutical K.K., Tokyo, Japan, 4. Department of Neuropsychiatry, Toho University Faculty of Medicine, Tokyo, Japan, 5. Tokyo Metropolitan Matsuzawa Hospital, Tokyo, Japan, 6. Akitsukounoike Hospital, Nara, Japan, 7. Department of Psychiatry, Graduate School of Medicine, Tohoku University, Sendai, Japan, 8. Department of Neuropsychiatry, Kurume University School of Medicine, Fukuoka, Japan, 9. Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, Chiba, Japan, 10. National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo, Japan)
Keywords:ultra-high risk for psychosis